Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Blood (2024) 144 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2024-211588

Published: 2024

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood blood.2024025987.

https://doi.org/10.1182/blood.2024025987

Published: 2024

Includes: Supplemental data

Journal Articles

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Blood (2022) 140 (Supplement 1): 2091–2092.

https://doi.org/10.1182/blood-2022-157485

Published: 2022

Journal Articles

Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network

Adriana Plesa, Octavia Cadassou, Joris Gutrin, Marine Villard, Christophe Roumier, Meyling Cheok, Florent Dumezy, Claude Preudhomme, Hélène Lapillonne, Arnaud Petit, Guy Leverger, Carine Halfon-Domenech, Cecile Renard, Yves Bertrand, Charles Dumontet, Sebastien Viel, Veronique Maguer-Satta, Thierry Walzer

Blood (2021) 138 (Supplement 1): 2375.

https://doi.org/10.1182/blood-2021-154181

Published: 2021

Journal Articles

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Eileen M Boyle, MD MSc, Faith E. Davies, MD, Shayu Deshpande, Ruslana G. Tytarenko, MS, Cody Ashby, PhD, Yan Wang, Christopher P. Wardell, PhD MSc, BSc, Michael A Bauer, PhD, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Louis Williams, MD MBA, Thierry Facon, MD, Charles Dumontet, Bart Barlogie, MD PhD, Gareth Morgan, MDPhDFRCP, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 4333.

https://doi.org/10.1182/blood-2019-126679

Published: 2019

Journal Articles

The genomic landscape of plasma cells in systemic light chain amyloidosis

Blood (2018) 132 (26): 2775–2777.

https://doi.org/10.1182/blood-2018-08-872226

Published: 2018

Includes: Supplemental data

Journal Articles

Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria

Eileen M Boyle, MD MSc, Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Yan Wang, Michael A Bauer, PhD, Shayu Deshpande, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Christopher Wardell, PhD, Niels Weinhold, PhD, Thierry Facon, Charles Dumontet, Gareth Morgan, MD, Faith E. Davies, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2018-99-117193

Published: 2018

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families

Alyssa I. Clay-Gilmour, BS, PhD, Nicola J Camp, PhD, Xiaomu Wei, PhD, Aaron D. Norman, Jason P Sinnwell, MS, Delphine Demangel, Rosalie Griffin Waller, BS, Charles Dumontet, James McKay, Kenneth Offit, MD, Siwei Chen, Daniel R O'Brien, S. Vincent Rajkumar, MD, Robert Klein, PhD, Shaji K. Kumar, MD, Steven Lipkin, MD PhD, Susan L. Slager, PhD, Celine M. Vachon, PhD

Blood (2018) 132 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2018-99-119320

Published: 2018

Journal Articles

Natural Killer Cells Display an Activated Phenotype but Reduced Effector Functions in Obese Patients

Sebastien Viel, Laurie Besson, Emily Charrier, Jacques Bienvenu, Emmanuel Disse, Thierry Walzer, Charles Dumontet

Blood (2015) 126 (23): 3430.

https://doi.org/10.1182/blood.V126.23.3430.3430

Published: 2015

Journal Articles

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Blood (2014) 124 (21): 3421.

https://doi.org/10.1182/blood.V124.21.3421.3421

Published: 2014

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Yesim G. Dargaud, MDPhD, Marc Fouassier, MD, Sophie Ducastelle, MD, Philippe Moreau, MD, Charles Dumontet, MD PhD, Mauricette Michallet, MD PhD, Jean-Claude Bordet, Claude Negrier, MD PhD

Blood (2014) 124 (21): 2037.

https://doi.org/10.1182/blood.V124.21.2037.2037

Published: 2014

Journal Articles

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Blood (2014) 124 (21): 2044.

https://doi.org/10.1182/blood.V124.21.2044.2044

Published: 2014

Journal Articles

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Florence Magrangeas, Rowan Kuiper, BSc, Hervé Avet-loiseau, MD PhD, Wilfried Gouraud, Catherine Guérin, Henri Der Sakissian, Jérôme Suhard, Michel Attal, Pieter Sonneveld, MDPhD, Charles Dumontet, MD PhD, Philippe Moreau, Mark van Duin, PhD, Loic Campion, MD, Stephane Minvielle

Blood (2014) 124 (21): 2057.

https://doi.org/10.1182/blood.V124.21.2057.2057

Published: 2014

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Jean El-Cheikh, MD PhD, Stéphane Morisset, Stat., Anne Sirvent, MD, Oumedaly Reman, MD, Jérôme Cornillon, MD, Reza Tabrizi, MD, Noel Milpied, MD, Jean-Luc Harousseau, MD, Hélène Labussière-Wallet, MD, Franck E. Nicolini, MD, PhD, Charles Dumontet, M. D., Ph.D., Mohamad Mohty, Michel Attal, MD, Didier Blaise, MD, Philippe Moreau, MD, Hervé Avet-Loiseau, MD, PhD

Blood (2012) 120 (21): 3116.

https://doi.org/10.1182/blood.V120.21.3116.3116

Published: 2012

Journal Articles

Higher Percentage of CD34 + CD38 − Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML

Adriana Plesa, MD, Mohamed Elhamri, PhD, Gilles Clapisson, Eve Mattei, Sophie Gazzo, PhD, Olivier Hequet, MD, Mauricette Michallet, MD, PhD, Charles Dumontet, MD, PhD, Xavier Thomas, MD

Blood (2012) 120 (21): 1485.

https://doi.org/10.1182/blood.V120.21.1485.1485

Published: 2012

Journal Articles

Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma

Lars-Petter Jordheim, PhD, Vincent Ribrag, MD, Herve Ghesquieres, MD, PhD, Sophie Pallardy, Richard Delarue, MD, Herve Tilly, Corinne Haioun, MD, PhD, Fabrice Jardin, Gilles Salles, MD, Charles Dumontet, MD, PhD

Blood (2012) 120 (21): 1616.

https://doi.org/10.1182/blood.V120.21.1616.1616

Published: 2012

Journal Articles

Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium

Blood (2011) 118 (21): 5014.

https://doi.org/10.1182/blood.V118.21.5014.5014

Published: 2011

NARROW

Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

The genomic landscape of plasma cells in systemic light chain amyloidosis

Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families

Natural Killer Cells Display an Activated Phenotype but Reduced Effector Functions in Obese Patients

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Higher Percentage of CD34 + CD38 − Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML

Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma

Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only